Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
P Thomas, B Vincent, C George… - Indian Journal of …, 2019 - journals.lww.com
Methods: This study included 71 NSCLC patients who received EGFR-TKIs between 2013
and 2016. Adverse drug reaction of both erlotinib (n= 37) and gefitinib (n= 34) was …
and 2016. Adverse drug reaction of both erlotinib (n= 37) and gefitinib (n= 34) was …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
[HTML][HTML] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - Elsevier
PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …